Evidence map›Paper›PMID 40429923›Full record

SynthesisInternational journal of molecular sciences2025

Sodium-Glucose Cotransporter-2 Inhibitors in Liver Cirrhosis: A Systematic Review of Their Role in Ascites Management, Slowing Disease Progression, and Safety.

Sudheer Dhoop, Sami Ghazaleh, Luke Roberts, Mohammed Shehada, Manthanbhai Patel, Wade-Lee Smith, Sana Rabeeah, Bisher Sawaf, Priya Vadehra, Benjamin Hart and 1 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Exploring Cirrhosis: Insights into Advances in Therapeutic Strategies.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sudheer DhoopDepartment of Internal Medicine, The University of Toledo, 3333 Glendale Ave., Toledo, OH 43614, USA.ORCID 0009-0009-5344-3191
Sami GhazalehDivision of Gastroenterology and Hepatology, The University of Toledo, 3333 Glendale Ave., Toledo, OH 43614, USA.
Luke RobertsCollege of Medicine and Life Sciences, The University of Toledo, 3000 Arlington Ave., Toledo, OH 43614, USA.
Mohammed ShehadaDepartment of Internal Medicine, The University of Toledo, 3333 Glendale Ave., Toledo, OH 43614, USA.
Manthanbhai PatelDepartment of Internal Medicine, The University of Toledo, 3333 Glendale Ave., Toledo, OH 43614, USA.
Wade-Lee SmithUniversity Library, The University of Toledo, 2801 W. Bancroft St., Toledo, OH 43606, USA.ORCID 0000-0003-1744-8525
Sana RabeeahDepartment of Internal Medicine, The University of Toledo, 3333 Glendale Ave., Toledo, OH 43614, USA.
Bisher SawafDepartment of Internal Medicine, The University of Toledo, 3333 Glendale Ave., Toledo, OH 43614, USA.ORCID 0000-0001-6751-619X
Priya VadehraDepartment of Biological Sciences, Wayne State University, 4841 Cass Ave., Detroit, MI 48201, USA.ORCID 0009-0002-7211-9118
Benjamin HartDivision of Gastroenterology and Hepatology, The University of Toledo, 3333 Glendale Ave., Toledo, OH 43614, USA.
Mona HassanDivision of Gastroenterology and Hepatology, The University of Toledo, 3333 Glendale Ave., Toledo, OH 43614, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) are widely used for type 2 diabetes mellitus (T2DM), conferring cardiovascular and renal benefits with evidence supporting their role in metabolic-associated steatotic liver disease (MASLD), the fastest rising etiology for liver cirrhosis. Our study collects and synthesizes all available data on SGLT2I use in liver cirrhosis to summarize their potential benefits and risks. We systematically reviewed the literature on SGLT2I use in adults with cirrhosis, focusing on 6 outcome domains, including ascites reduction, disease progression, hemodynamics, acute kidney injury (AKI), electrolyte abnormalities, and infection risk. We identified 16 studies: compensated (

Indexed as

AscitesLiver CirrhosisSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Disease ProgressionHumansSodium-Glucose Transporter 2 InhibitorsAKIelectrolyte abnormalitieshepatic decompensationhypotensioninfectionrefractory ascitesSGLT2I

Identifiers

PMID40429923
PMCPMC12112422

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.